- After Favipiravir enters the cell, it is converted into favipiravir ibofuranosyl-5'-triphosphate (favipiravir-RTP)
- Favipiravir-RTP inhibits the activity of the virus's RNA polymerase (RdRp)

Smith College

This drug works by hindering the viral RNA polymerase, thus stopping viral replication. It requires doses at the higher end of the dosing range to tread COVID-19. Overall, it is well tolerated, but it may have some mild effects. With limited clinical experience for treating COVID-19, Favipiravir is not accessible in the US for clinical use. 

- Toxicities of Favipiravir 
- Favipiravir mechanism of action 

Favipiravir as a treatment for COVID-19

Du, Y. X., & Chen, X. P. (2020). Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clinical Pharmacology & Therapeutics.

https://doi.org/10.1002/cpt.1844
https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1844

Favipiravir: Pharmacokinetics and Concerns
About Clinical Trials for 2019-nCoV Infection

Toxicities include hyperuricemia, diarrhea, elevated levels of transaminases, and reduction in neutrophil count

Learn Before

Related